Teppo Konsta, Airaksinen K E Juhani, Halminen Olli, Jaakkola Jussi, Haukka Jari, Kouki Elis, Luojus Alex, Putaala Jukka, Salmela Birgitta, Linna Miika, Aro Aapo L, Mustonen Pirjo, Hartikainen Juha, Lip Gregory Y H, Lehto Mika
Heart Centre, Turku University Hospital, Turku, Finland; Biotechnology Unit, University of Turku, Turku, Finland.
Heart Centre, Turku University Hospital, Turku, Finland.
JACC Clin Electrophysiol. 2025 Mar;11(3):583-592. doi: 10.1016/j.jacep.2024.10.029. Epub 2024 Dec 18.
Atrial fibrillation (AF) is a major risk factor for ischemic stroke (IS), but whether the magnitude of this risk has changed over time is unknown.
This study sought to investigate temporal trends in IS rates in patients with incident AF before oral anticoagulant agent (OAC) therapy.
The nationwide FinACAF (Finnish Anticoagulation in Atrial Fibrillation) study covers patients with AF at all levels of care in Finland from 2007 to 2018. A 4-week quarantine period from AF diagnosis was applied, and only follow-up time without OAC therapy was included. Incidence rates of IS were computed in 4-year intervals in relation to sex and non-sex CHADS-VASc (ie, CHADS-VA) score values.
In total, 129,789 patients with new-onset AF were identified (49.2% women; mean age: 71.4 ± 14.5 years). Between the calendar year intervals of 2007-2010 and 2015-2018, the patients' mean CHADS-VA score increased from 2.5 to 3.0, and concurrently the overall IS rate decreased by 25% from 36.7 to 27.6 events per 1,000 patient-years. This trend was driven by a 32% decrease of IS rate in women, particularly among those with higher age and CHADS-VA scores. The IS rate in patients with a CHADS-VA score of 1 was 8.2 events per 1,000 patient-years and remained stable across the study period.
The initial IS risk in AF patients, before the initiation of OAC therapy, has decreased by 25% between 2007 and 2018 despite an increase in both age and stroke risk scores. The decrease has been most pronounced in older women with high stroke risk scores.
心房颤动(AF)是缺血性卒中(IS)的主要危险因素,但该风险的程度是否随时间变化尚不清楚。
本研究旨在调查口服抗凝剂(OAC)治疗前新发AF患者的IS发生率的时间趋势。
全国性的芬兰心房颤动抗凝研究(FinACAF)涵盖了2007年至2018年芬兰各级医疗机构中患有AF的患者。采用从AF诊断起4周的隔离期,仅纳入无OAC治疗的随访时间。根据性别和非性别CHADS-VASc(即CHADS-VA)评分值,每4年计算一次IS发生率。
共识别出129789例新发AF患者(女性占49.2%;平均年龄:71.4±14.5岁)。在2007 - 2010年和2015 - 2018年的日历年间隔期间,患者的平均CHADS-VA评分从2.5增加到3.0,同时总体IS发生率从每1000患者年36.7例下降了25%至27.6例。这一趋势是由女性IS发生率下降32%驱动的,尤其是在年龄较大和CHADS-VA评分较高的女性中。CHADS-VA评分为1的患者的IS发生率为每1000患者年8.2例,在整个研究期间保持稳定。
在开始OAC治疗之前,AF患者的初始IS风险在2007年至2018年间下降了25%,尽管年龄和卒中风险评分均有所增加。这种下降在卒中风险评分高的老年女性中最为明显。